Reig Jofre, member of CataloniaBio & HealthTech, announces an investment of 5.8 million euros in the biotechnological company Leanbio, also a member. This investment aims at vertical integration in the development, characterization, and production of biotechnological-based active ingredients.
The company capitalizes on its existing facilities and know-how in formulation, stabilization, characterization, and industrial scaling, as well as in the aseptic production of injectable pharmaceutical finished product.
Reig Jofre is evolving from the pharmaceutical "fill & finish" process towards vertical integration in the production of innovative biotechnological and biosimilar products. This advancement is carried out hand in hand with Leanbio, in which Reig Jofre has held a 10% stake to date. The operation, structured through equity and debt, has been led by Reig Jofre together with other partners of Leanbio. As a result, the company will increase its stake in Leanbio to reach 24%, committing to continue increasing its presence as the expansion plan progresses.
Comments